Liver Diseases

36 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Liver Diseases
Treatment and conditionWhere it standsTrials
Atezolizumab for fatty liverPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Baclofen for liver diseases, alcoholicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Berberine ursodeoxycholate for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Bevacizumab + atezolizumab for fatty liverPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cannabidiol for liver cirrhosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemically induced pluripotent stem cells biological Artificial Liver for liver failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
DR10624 Injection for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ECC0509 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ECC0509 + ECC4703 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ECC4703 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Efruxifermin for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
EGEN-5784 (genetically engineered porcine liver) + metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx) for acute-on-chronic liver failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Empagliflozin for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for fatty liverPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver cirrhosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ex vivo perfusion of six-gene-edited porcine liver + Multi-drug immunosuppressive therapy for liver failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Faecal microbiota transplantation for hepatitis, alcoholicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Faecal microbiota transplantation for liver cirrhosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fenofibrate for liver cirrhosis, biliaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fenofibrate in Combination With Ursodeoxycholic Acid for liver cirrhosis, biliaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Food Security Screening & Referral Program for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
HepaCure for hepatitisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HepaCure for liver failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HSK31679 for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
HU6 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
miRNA Biomarker-Guided Immunosuppression Minimization for liver diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Obeticholic acid for fatty liverTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pegargiminase for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PolyPill for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
SNP-610 for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Standard Soy Milk for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Survodutide for liver diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Survodutide for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Very-low calorie diet for fatty liverTrial registered, as of 19 Nov 2026 (not yet checked by a person)1